{
    "answer": "Immunology segment net sales for the full year 2024, as reported, were USD 15.2 billion, representing a 24% growth compared to the full year 2023 immunology segment sales of USD 10.6 billion (from a December 31, 2023, date).\n\nCosentyx's net sales in the immunology segment for the full year 2024, reported and constant currency basis, were USD 6 billion (reported USD 13.15 billion, a 25% reported growth, and a 22% constant currency growth). These results were driven by new launches in healthcare specialty injections (HS), under the US IV launch. This included Xolair sales adjusted to immunology segment.",
    "ground_truth": "$6,141,000,000; 23% increase (reported); 25% increase (constant currency)",
    "rewards": [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
    ],
    "reward_sum": 0,
    "turns": 8,
    "search count": 6,
    "script count": 0,
    "summary count": 0,
    "context lengths": [
        923,
        2321,
        3702,
        5616,
        7455,
        9550,
        10377,
        12158
    ]
}